Implantable pump fires chemo straight at pancreatic cancer
NCT ID NCT07481383
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This early-phase trial tests a new device that is surgically placed on the pancreas to deliver the chemotherapy drug gemcitabine directly to the tumor. The goal is to see if this approach is safe and causes fewer side effects than standard IV chemo. The study involves 12 people with nonresectable pancreatic cancer who will receive treatment for 8 weeks and be followed for 24 weeks total.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gemcitabine delivered via an implantable device
- What this could lead to
- If it works, this could offer a way to treat pancreatic cancer with fewer side effects by delivering chemo directly to the tumor.
- What could go wrong
- This is a very early, small trial with only 12 people. The device requires surgery to implant, and it may not work or could cause complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA NON-RESECTABLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan Health
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
West Virginia University
RECRUITINGMorgantown, West Virginia, 26506, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.